Covid19, SARS-CoV Infection
Conditions
Keywords
vitamin c, melatonin
Brief summary
This is a double-blind placebo controlled trial that seeks to evaluate the impact of melatonin and vitamin C on symptoms and outcomes of patients with COVID-19.
Interventions
DIETARY_SUPPLEMENTVitamin C
1000mg Vitamin C, at bedtime
DIETARY_SUPPLEMENTmelatonin
10mg melatonin, at bedtime
DIETARY_SUPPLEMENTPlacebo
Placebo at bedtime
OTHERSymptom Survey
Daily symptom survey to be completed by patient electronically
Sponsors
Lancaster General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* COVID-19 positive test (outpatient testing), * Age \>50 (chosen based greater risk for older patients to be vitamin deficient, age \>65 not used so as not to be too restrictive in the inclusion criteria) * Experiencing symptoms for \<5 days prior to enrollment * Able to read and write in English or Spanish * Able to access REDCap daily * Valid email address * Current has a Lancaster General Health primary care physician
Exclusion criteria
* COVID-19 test ordered pre-procedure for asymptomatic screening * Currently taking vitamin C supplements * Currently taking melatonin supplements * Currently hospitalized * Deceased * Currently pregnant * Currently incarcerated
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Symptom Severity | 14 days | Symptom severity will be tracked electronically |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Symptom progression | 14 days | Determine symptom course of those with moderate or severe symptoms |
Countries
United States
Outcome results
None listed